Draft:Gene Solutions
This may take 2 months or more, since drafts are reviewed in no specific order. There are 2,469 pending submissions waiting for review.
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
 | Review waiting, please be patient.
This may take 2 months or more, since drafts are reviewed in no specific order. There are 2,469 pending submissions waiting for review.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Reviewer tools
|
Submission declined on 28 March 2026 by Carolina2k22 (talk).
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
This draft has been resubmitted and is currently awaiting re-review. |  |
This draft's references do not show that the subject meets Wikipedia's criteria for inclusion for organizations and companies. The draft requires multiple published secondary sources that:
Declined by WeWake 7 months ago.
| |
Submission declined on 21 July 2025 by Pythoncoder (talk). This draft appears to contain text generated by a large language model (such as ChatGPT). You cannot use LLMs to generate article content.
Declined by Pythoncoder 12 months ago.LLM-generated pages with certain obvious signs of being machine generated may be deleted without notice. Instead, only summarize in your own words a range of independent, reliable, published sources that discuss the subject. See the advice page on large language models for more information. | |
| Type | Private |
|---|---|
| Industry | Biotechnology |
| Founded | 2017 |
| Founders | Nguyễn Hoài Nghĩa, Giang Hoa, Nguyễn Hữu Nguyên |
| Products | triSure, SPOT-MAS, K-TRACK, K-4CARE |
| Website | genesolutions |
Gene Solutions is a Singapore-headquartered biotechnology company that develops and provides genetic testing services in the fields of reproductive health, including noninvasive prenatal testing (NIPT), and oncology, focusing on multi-cancer early detection and tumor monitoring. Gene Solutions operates two College of American Pathologists CAP-accredited laboratories in Singapore and Vietnam.
History
In 2017, Nguyễn Hoài Nghĩa, Giang Hoa, and Nguyễn Hữu Nguyên founded Gene Solutions in Vietnam.[1]
In 2018, Gene Solutions launched triSure, its first NIPT product, with an initial focus on reproductive genetics in Vietnam.
In April 2022, Gene Solutions expanded into oncology with the introduction of cancer screening product - SPOT-MAS, a liquid biopsy workflow for multi-cancer early detection.[2][3]
In late 2022, Gene Solutions launched K-TRACK, a circulating tumor DNA (ctDNA) test for molecular residual disease monitoring.
In September 2023, Gene Solutions released K-4CARE, a comprehensive genomic and transcriptomic profiling test for therapy selection.[4]
In May 2026, SPOT-MAS 10 received the Food and Drug Administration (FDA) Breakthrough Device Designation.[5]
Funding
In 2021, Gene Solutions received a $15 million investment from Mekong Capital's Mekong Enterprise Fund IV,[6] followed by a $21 million Series B round in 2023.[7]
In 2025, Gene Solutions received an investment of an undisclosed amount from the Singapore-based healthcare firm August Global Partners to support regional expansion and technology development.[8]
Operations
By 2026, Gene Solutions had expanded its operations across Southeast Asia, Asia-Pacific, the Middle East, and the Americas, including Singapore, Vietnam, Thailand, Indonesia, Malaysia, the Philippines, China, Hong Kong SAR, Taiwan, India, Turkey, Brazil, and the USA.[9][10]
References
- ^ "Intention to lead the market". forbes.vn.
- ^ "SPOT-MAS Test Launch". vnexpress.net.
- ^ "Vietnam's Gene Solutions Looks to Expand MCED Test Market After Strong Validation Data". genomeweb.
- ^ "Precision medicine contributes to 'less invasive' healthcare". vnexpress.net.
- ^ "Gene Solutions Announces FDA Breakthrough Device Designation for SPOT-MAS 10 Multi-Cancer Screening Blood Test". oncodaily.com.
- ^ "Mekong Capital invests additional $21 million in Vietnamese gene testing company". The Investor. 2023.
- ^ "Gene Solutions raises $21m Series B targeting regional expansion". Tech in Asia. 2023.
- ^ "Singapore's August Global Partners invests in Gene Solutions". Reuters. 9 January 2025.
- ^ "Biotech company Gene Solutions partners with Pangea Laboratory to validate ctDNA tests for cancer screening in US". sp-edge.
- ^ "Gene Solutions Market". Genesolutions.com.
Content Disclaimer
Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.
- The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
- There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
- It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
- Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
- Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.
Wikipedia articles must be written neutrally in a formal, impersonal, and dispassionate way. They should not read like a blog post, advertisement, or fan page. Rewrite the draft to remove:
Instead, only summarize in your own words a range of independent, reliable, published sources that discuss the subject.
If you have a conflict of interest (e.g. you are the subject, an employee, or a relative) or are being paid to edit, you must disclose this to comply with Wikipedia's Terms of Use.